Prelude Therapeutics (PRLD) Total Non-Current Liabilities (2019 - 2026)

Prelude Therapeutics has reported Total Non-Current Liabilities for 8 years, with the latest figure at $56.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 61.69% year-over-year to $56.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.7 million (up 61.69% YoY) and the FY2025 annual result came in at $69.8 million, up 70.48% from the prior year.
• Total Non-Current Liabilities retreated to $56.7 million in Q1 2026 per PRLD's latest filing, from $69.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $69.8 million in Q4 2025 and troughed at $15.2 million in Q2 2023.
• A 5-year average of $32.1 million and a median of $33.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities dropped 21.65% in 2023, then soared 155.43% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $21.7 million in 2022, then soared by 71.58% to $37.2 million in 2023, then gained by 10.02% to $41.0 million in 2024, then surged by 70.48% to $69.8 million in 2025, then declined by 18.84% to $56.7 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $56.7 million, $69.8 million, and $33.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.